Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Nor does short-term oral exposure evidence establish the safety of other routes, formulations, long-term repeated exposure, or independently manufactured materials
AOD-9604 Clinical Evidence Context AOD-9604 is unusual among research peptides because it actually completed real Phase 1 and Phase 2 clinical trials
Subtle changes at 23 weeks
Any reference to biological activity or potential effects is based solely on preclinical or invitro findings and should not be interpreted as validated clinical outcomes
Dosing tiers: Topical application (creams containing 1-3% GHK-Cu) targets skin-specific aging: wrinkles, laxity, and hyperpigmentation
It appears on the FDAs approved Bulk Drug Substances List as Category 1
US$ 28.97
US$ 24.39
US$ 28.78
&srotate=0)
US$ 20.23
US$ 25.60
